secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K/A
Filed at:   2025-09-08T23:59:59+00:00
Accession:  0000950170-25-113599
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics presents positive aficamten data at ESC 2025; PDUFA Dec 26, 2025
-----------------------------------------------------------------------------

- MAPLE-HCM: aficamten improved cardiac structure/function vs metoprolol (p<0.001 for diastolic function, SAM reduction); published in JACC.
- New analysis shows aficamten AF incidence 1.5%/year, consistent with HCM prediction model (3.6%/year) and healthy model (1.4%/year); published in Heart Rhythm.
- FOREST-HCM: 93% of patients had ≥1 NYHA class improvement at 96 weeks; sustained hemodynamic benefits with low LVEF <50% (0.3% discontinuation).
- Integrated safety (463 patients, ~700 patient-years): aficamten well-tolerated, AE profile similar to placebo; new-onset AF 1.9% vs placebo 2%.
- FDA NDA under review; PDUFA target action date December 26, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017025113599/0000950170-25-113599-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017025113599/cytk-20250831.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-113599

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer